Skip to content
Article Rich – Lifestyle
Author:
AbbVie
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
June 29, 2026
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
June 29, 2026
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
June 26, 2026
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
June 26, 2026
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective’s Entrepreneur Class of 2026
June 24, 2026
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
June 23, 2026
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
June 23, 2026
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
June 23, 2026
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
June 22, 2026
AbbVie Declares Quarterly Dividend
June 18, 2026
1
2
Next Page
→